357336-20-0 Categories: , , ,
  • # LGM Pharma is a Brivaracetam CAS# 357336-20-0 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Brivaracetam
  • CAS #: 357336-20-0
  • Mode of Action:

    Clearance of Brivaracetam may be reduced in patients with hepatic insufficiency, however the photo paroxysmal response model in patients diagnosed with photosensitive epilepsy has proven to be effective.

  • Pharmacodynamics:

    Brivaracetam is chemically related to the AED Levetiracetam and possesses a natural binding affinity for the 2A synaptic vesicle protein. A higher potency in suppressing epileptiform responses in vitro, roughly ten-fold above that of Levetiracetam, has been shown in comprehensive studies of Brivaracetam. The ability of Brivaracetam to suppress various seizure types in studies, including genetic forms of epilepsy in patients offers patients a novel inhibitory therapy.  

  • Metabolism:

    Brivaracetam has a half-life of eight hours and virtually complete bioavailability. As Brivaracetam is mainly metabolized via hydrolysis of the acetamide group, as well as CYP2C8-mediated hydroxylation, its metabolites are not pharmacologically active.

  • Toxicity:

    Brivaracetam has been tested in a comprehensive trials for toxicology, safety and genotoxicity. A low acute toxicity has been found in patients who received therapy with Brivaracetam. Commonly reported adverse effects have been documented as mild, and include fatigue, dizziness, headache and somnolence.  

  • IUPAC: 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS, 4R)-
  • PubChem: 9837243
  • Formula: C11-H20-N2-O2
  • Molecular Mass: 212.291
  • Synonyms: (2S)-2-((4R)-2-Oxo-4-propylpyrrolidin-1-yl)butanamide, Brivaracetam, UCB 34714, UCB34714, UNII-U863JGG2IA
  • SMILES: CCC[C@@H]1CC(=O)[N@@](C1)C(CC)C(=O)N
  • InChl: 1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9?/m1/s1
  • General Reference:
    1. von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics. 2007 Jan;4(1):84-7.
    2. Br J Pharmacol. 2008 Aug; 154(8): 1555–1557.
    3. Alzheimers Res Ther. 2015 May 5;7(1):25. doi: 10.1186/s13195-015-0110-9. eCollection 2015.
    4. Ryvlin, P., et al., Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia, 2014. 55(1):47-56.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants


  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service